Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

NCT04823403 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris